Impact of Osteoporosis and Its Treatment on Oral Health


      Osteoporosis has emerged as a major health problem affecting middle-aged and older individuals. It is characterized by a reduced bone mass and strength, resulting in increased susceptibility to fractures. The disease is associated with several risk factors, and increasing evidence suggests that it may be associated with oral health conditions such as periodontal disease, reduced jaw bone density and tooth loss. Besides the effects of osteoporosis on oral health, bisphosphonate-related osteonecrosis of the jaws is a major concern to the dentist. Bisphosphonate-related osteonecrosis of the jaws is a recently described adverse effect of bisphosphonate therapy. The exact mechanisms by which these drugs cause necrosis of the jaws remain unclear, and a true cause-and-effect relationship between osteonecrosis of the jaw and bisphosphonate use has not yet been established. Hence, any form of invasive dentoalveolar treatment should be performed with caution in patients taking bisphosphonates. This review discusses current evidence on osteoporosis and its treatment implications as a risk factor in the development of various oral diseases.

      Key Indexing Terms

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of the Medical Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Cummings S.
        • Melton L.
        Epidemiology and outcomes of osteoporotic fractures.
        Lancet. 2002; 359: 1761-1767
        • Kanis J.A.
        Osteoporosis and osteopenia.
        J Bone Miner Res. 1990; 5: 209-211
        • Riggs B.
        • Wahner H.
        • Seeman E.
        • et al.
        Changes in bone mineral density of the proximal femur and spine with aging: differences between the postmenopausal and senile osteoporosis syndromes.
        J Clin Invest. 1982; 70: 716
        • Raisz L.
        Pathogenesis of osteoporosis: concepts, conflicts, and prospects.
        J Clin Invest. 2005; 115: 3318-3325
        • Jeffcoat M.
        The association between osteoporosis and oral bone loss.
        J Periodontol. 2005; 76: 2125-2132
        • Poole K.
        • Compston J.
        Osteoporosis and its management.
        Br Med J. 2006; 333: 1251
        • Riggs B.
        • Khosla S.
        • Melton III., L.
        Sex steroids and the construction and conservation of the adult skeleton.
        Endocr Rev. 2002; 23: 279
        • Vidal O.
        • Lindberg M.
        • Hollberg K.
        • et al.
        Estrogen receptor specificity in the regulation of skeletal growth and maturation in male mice.
        Proc Natl Acad Sci U S A. 2000; 97: 5474
        • Prestwood K.
        • Pilbeam C.
        • Burleson J.
        • et al.
        The short-term effects of conjugated estrogen on bone turnover in older women.
        J Clin Endocrinol Metab. 1994; 79: 366
        • Deng H.
        • Xu F.
        • Huang Q.
        • et al.
        A whole-genome linkage scan suggests several genomic regions potentially containing quantitative trait loci for osteoporosis.
        J Clin Endocrinol Metab. 2002; 87: 5151
        • Kaufman J.M.
        • Ostertag A.
        • Saint-Pierre A.
        • et al.
        Genome-wide linkage screen of bone mineral density (BMD) in European pedigrees ascertained through a male relative with low BMD values: evidence for quantitative trait loci on 17q21-23, 11q12-13, 13q12-14, and 22q11.
        J Clin Endocrinol Metab. 2008; 93: 3755-3762
        • Albertsson D.
        • Mellstrom D.
        • Petersson C.
        • et al.
        Hip and fragility fracture prediction by 4-item clinical risk score and mobile heel BMD: a women cohort study.
        BMC Musculoskelet Disord. 2010; 11: 55
        • Robbins J.
        • Aragaki A.K.
        • Kooperberg C.
        • et al.
        Factors associated with 5-year risk of hip fracture in postmenopausal women.
        JAMA. 2007; 298: 2389-2398
        • Kelepouris N.
        • Harper K.
        • Gannon F.
        • et al.
        Severe osteoporosis in men.
        Ann Intern Med. 1995; 123: 452
        • Persson R.E.
        • Hollender L.G.
        • Powell L.V.
        • et al.
        Assessment of periodontal conditions and systemic disease in older subjects. I. Focus on osteoporosis.
        J Clin Periodontol. 2002; 29: 796-802
        • Geurs N.C.
        • Lewis C.E.
        • Jeffcoat M.K.
        Osteoporosis and periodontal disease progression.
        Periodontol 2000. 2003; 32: 105-110
        • Krall E.A.
        The periodontal-systemic connection: implications for treatment of patients with osteoporosis and periodontal disease.
        Ann Periodontol. 2001; 6: 209-213
        • Jagelaviciene E.
        • Kubilius R.
        The relationship between general osteoporosis of the organism and periodontal diseases.
        Medicina (Kaunas). 2006; 42: 613-618
        • Mohammad A.R.
        • Brunsvold M.
        • Bauer R.
        The strength of association between systemic postmenopausal osteoporosis and periodontal disease.
        Int J Prosthodont. 1996; 9: 479-483
        • Daniell H.W.
        Postmenopausal tooth loss. Contributions to edentulism by osteoporosis and cigarette smoking.
        Arch Intern Med. 1983; 143: 1678-1682
        • Erdogan O.
        • Incki K.K.
        • Benlidayi M.E.
        • et al.
        Dental and radiographic findings as predictors of osteoporosis in postmenopausal women.
        Geriatr Gerontol Int. 2009; 9: 155-164
        • Gur A.
        • Nas K.
        • Kayhan O.
        • et al.
        The relation between tooth loss and bone mass in postmenopausal osteoporotic women in Turkey: a multicenter study.
        J Bone Miner Metab. 2003; 21: 43-47
        • Moedano D.E.
        • Irigoyen M.E.
        • Borges-Yanez A.
        • et al.
        Osteoporosis, the risk of vertebral fracture, and periodontal disease in an elderly group in Mexico City.
        Gerodontology. 2011; 28: 19-27
        • Yoshihara A.
        • Seida Y.
        • Hanada N.
        • et al.
        The relationship between bone mineral density and the number of remaining teeth in community-dwelling older adults.
        J Oral Rehabil. 2005; 32: 735-740
        • Tezal M.
        • Wactawski-Wende J.
        • Grossi S.G.
        • et al.
        The relationship between bone mineral density and periodontitis in postmenopausal women.
        J Periodontol. 2000; 71: 1492-1498
        • Wactawski-Wende J.
        • Hausmann E.
        • Hovey K.
        • et al.
        The association between osteoporosis and alveolar crestal height in postmenopausal women.
        J Periodontol. 2005; 76: 2116-2124
        • Kuo L.C.
        • Polson A.M.
        • Kang T.
        Associations between periodontal diseases and systemic diseases: a review of the inter-relationships and interactions with diabetes, respiratory diseases, cardiovascular diseases and osteoporosis.
        Public Health. 2008; 122: 417-433
        • Payne J.
        • Reinhardt R.
        • Nummikoski P.
        • et al.
        The association of cigarette smoking with alveolar bone loss in postmenopausal females.
        J Clin Periodontol. 2000; 27: 658-664
        • Jabbar S.
        • Drury J.
        • Fordham J.
        • et al.
        Plasma vitamin D and cytokines in periodontal disease and postmenopausal osteoporosis.
        J Periodontal Res. 2011; 46: 97-104
        • Bando K.
        • Nitta H.
        • Matsubara M.
        • et al.
        Bone mineral density in periodontally healthy and edentulous postmenopausal women.
        Ann Periodontol. 1998; 3: 322
        • Xie Q.
        • Ainamo A.
        Association of edentulousness with systemic factors in elderly people living at home.
        Community Dent Oral Epidemiol. 1999; 27: 202-209
        • Scheidt-Nave C.
        • Bismar H.
        • Leidig-Bruckner G.
        • et al.
        Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause.
        J Clin Endocrinol Metab. 2001; 86: 2032-2042
        • Reddy M.S.
        Osteoporosis and periodontitis: discussion, conclusions, and recommendations.
        Ann Periodontol. 2001; 6: 214-217
        • Johnson R.B.
        • Gilbert J.A.
        • Cooper R.C.
        • et al.
        Alveolar bone loss one year following ovariectomy in sheep.
        J Periodontol. 1997; 68: 864-871
        • Malan J.
        • Ettinger K.
        • Naumann E.
        • et al.
        The relationship of denosumab pharmacology and osteonecrosis of the jaws.
        Oral Surg Oral Med Oral Pathol Oral Radiol. 2012; 114: 671-676
        • Bellido T.
        • Plotkin L.I.
        Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability.
        Bone. 2011; 49: 50-55
        • Greenspan S.
        • Harris S.
        • Bone H.
        • et al.
        Bisphosphonates: safety and efficacy in the treatment and prevention of osteoporosis.
        Am Fam Physician. 2000; 61: 2731-2736
        • Fleisch H.A.
        Bisphosphonates: preclinical aspects and use in osteoporosis.
        Ann Med. 1997; 29: 55-62
        • Russell R.
        • Rogers M.
        • Frith J.
        • et al.
        The pharmacology of bisphosphonates and new insights into their mechanisms of action.
        J Bone Miner Res. 1999; 14: 53
        • Raje N.
        • Woo S.B.
        • Hande K.
        • et al.
        Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw.
        Clin Cancer Res. 2008; 14: 2387-2395
        • Santini D.
        • Vincenzi B.
        • Hannon R.A.
        • et al.
        Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours.
        Oncol Rep. 2006; 15: 1351-1357
        • Sparidans R.W.
        • Twiss I.M.
        • Talbot S.
        Bisphosphonates in bone diseases.
        Pharm World Sci. 1998; 20: 206-213
        • Drake M.
        • Clarke B.
        • Khosla S.
        Bisphosphonates: mechanism of action and role in clinical practice.
        Mayo Clin Proc. 2008; 83: 1032-1045
        • Coleman R.
        Risks and benefits of bisphosphonates.
        Br J Cancer. 2008; 98: 1736-1740
        • Bagan J.
        • Scully C.
        • Sabater V.
        • et al.
        Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): a concise update.
        Oral Oncol. 2009; 45: 551-554
        • Reszka A.A.
        • Rodan G.A.
        Nitrogen-containing bisphosphonate mechanism of action.
        Mini Rev Med Chem. 2004; 4: 711-719
        • Leite A.F.
        • Figueiredo P.T.
        • Melo N.S.
        • et al.
        Bisphosphonate-associated osteonecrosis of the jaws. Report of a case and literature review.
        Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006; 102: 14-21
        • Ruggiero S.L.
        • Mehrotra B.
        • Rosenberg T.J.
        • et al.
        Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases.
        J Oral Maxillofac Surg. 2004; 62: 527-534
        • Fleisch H.
        Development of bisphosphonates.
        Breast Cancer Res. 2002; 4: 30-34
        • Hoff A.O.
        • Toth B.B.
        • Altundag K.
        • et al.
        Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates.
        J Bone Miner Res. 2008; 23: 826-836
        • Marx R.E.
        Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.
        J Oral Maxillofac Surg. 2003; 61: 1115-1117
        • Ficarra G.
        • Beninati F.
        • Rubino I.
        • et al.
        Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment.
        J Clin Periodontol. 2005; 32: 1123-1128
        • Gonzalez-Moles M.
        • Bagan-Sebastian J.
        Alendronate-related oral mucosa ulcerations.
        J Oral Pathol Med. 2000; 29: 514-518
        • Demerjian N.
        • Bolla G.
        • Spreux A.
        Severe oral ulcerations induced by alendronate.
        Clin Rheumatol. 1999; 18: 349-350
        • Sarasquete M.E.
        • Garcia-Sanz R.
        • Marin L.
        • et al.
        Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis.
        Blood. 2008; 112: 2709-2712
        • Marx R.E.
        • Sawatari Y.
        • Fortin M.
        • et al.
        Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
        J Oral Maxillofac Surg. 2005; 63: 1567-1575
        • Bilezikian J.P.
        Osteonecrosis of the jaw—do bisphosphonates pose a risk?.
        N Engl J Med. 2006; 355: 2278-2281
        • Javed F.
        • Almas K.
        Osseointegration of dental implants in patients undergoing bisphosphonate treatment: a literature review.
        J Periodontol. 2010; 81: 479-484
        • Kasai T.
        • Pogrel M.
        • Hossaini M.
        The prognosis for dental implants placed in patients taking oral bisphosphonates.
        J Calif Dent Assoc. 2009; 37: 39
        • Yarom N.
        • Yahalom R.
        • Shoshani Y.
        • et al.
        Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome.
        Osteoporos Int. 2007; 18: 1363-1370
        • Mashiba T.
        • Hirano T.
        • Turner C.H.
        • et al.
        Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib.
        J Bone Miner Res. 2000; 15: 613-620
        • Bodic F.
        • Hamel L.
        • Lerouxel E.
        • et al.
        Bone loss and teeth.
        Joint Bone Spine. 2005; 72: 215-221
        • Deckers M.M.
        • van Bezooijen R.L.
        • van der Horst G.
        • et al.
        Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A.
        Endocrinology. 2002; 143: 1545-1553
        • Giraudo E.
        • Inoue M.
        • Hanahan D.
        An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis.
        J Clin Invest. 2004; 114: 623-633
        • Reid I.R.
        • Bolland M.J.
        • Grey A.B.
        Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?.
        Bone. 2007; 41: 318-320
        • Marx R.
        Oral and Intravenous Bisphosphonate-Induced Osteonecrosis of the Jaws: History, Etiology.
        Prevention, and Treatment. Quintessence, Hanover Park (IL)2006
        • Woo S.
        • Hellstein J.
        • Kalmar J.
        Systematic review: bisphosphonates and osteonecrosis of the jaws.
        Ann Intern Med. 2006; 144: 753
        • Hewitt C.
        • Farah C.
        Bisphosphonate-related osteonecrosis of the jaws: a comprehensive review.
        J Oral Pathol Med. 2007; 36: 319-328
        • Pogrel M.
        Bisphosphonates and bone necrosis.
        J Oral Maxillofac Surg. 2004; 62: 391
        • Peter B.
        • Gauthier O.
        • Laib S.
        • et al.
        Local delivery of bisphosphonate from coated orthopedic implants increases implants mechanical stability in osteoporotic rats.
        J Biomed Mater Res A. 2006; 76: 133-143
        • Goss A.
        • Bartold M.
        • Sambrook P.
        • et al.
        The nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in dental implant patients: a South Australian case series.
        J Oral Maxillofac Surg. 2010; 68: 337-343
        • Stadelmann V.
        • Gauthier O.
        • Terrier A.
        • et al.
        Implants delivering bisphosphonate locally increase periprosthetic bone density in an osteoporotic sheep model. A pilot study.
        Eur Cell Mater. 2008; 16: 10-16
        • YIldIz A.
        • Esen E.
        • Kürkçü M.
        • et al.
        Effect of zoledronic acid on osseointegration of titanium implants: an experimental study in an ovariectomized rabbit model.
        J Oral Maxillofac Surg. 2010; 68: 515-523
        • Shabestari G.O.
        • Shayesteh Y.S.
        • Khojasteh A.
        • et al.
        Implant placement in patients with oral bisphosphonate therapy: a case series.
        Clin Implant Dent Relat Res. 2010; 12: 175-180
        • Starck W.
        • Epker B.
        Failure of osseointegrated dental implants after diphosphonate therapy for osteoporosis: a case report.
        Int J Oral Maxillofac Implants. 1995; 10: 74-78
        • Shirota T.
        • Nakamura A.
        • Matsui Y.
        • et al.
        Bisphosphonate-related osteonecrosis of the jaw around dental implants in the maxilla: report of a case.
        Clin Oral Implants Res. 2009; 20: 1402-1408
        • Serra M.
        • Llorca C.
        • Donat F.
        Oral implants in patients receiving bisphosphonates: a review and update.
        Med Oral Patol Oral Cir Bucal. 2008; 13: E755-60